Literature DB >> 33961754

Therapeutic Application of Alpha-1 Antitrypsin in COVID-19.

Felix Ritzmann1, Praneeth Chitirala1, Nadine Krüger2, Markus Hoffmann2,3, Wei Zuo4, Frank Lammert1,5, Sigrun Smola6, Naveh Tov7, Noga Alagem7, Philipp M Lepper1, Stefan Pöhlmann2,3, Christoph Beisswenger1, Christian Herr1, Robert Bals1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33961754     DOI： 10.1164/rccm.202104-0833LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

1.  Investigating the Link between Alpha-1 Antitrypsin and Human Neutrophil Elastase in Bronchoalveolar Lavage Fluid of COVID-19 Patients.

Authors:  Maura D'Amato; Valentina Vertui; Laura Pandolfi; Sara Bozzini; Tommaso Fossali; Riccardo Colombo; Anna Aliberti; Marco Fumagalli; Paolo Iadarola; Camilla Didò; Simona Viglio; Federica Meloni
Journal:  Curr Issues Mol Biol       Date:  2022-05-10       Impact factor: 2.976

Review 2.  A Review of Alpha-1 Antitrypsin Binding Partners for Immune Regulation and Potential Therapeutic Application.

Authors:  Michael E O'Brien; Grace Murray; Debananda Gogoi; Azeez Yusuf; Cormac McCarthy; Mark R Wormald; Michelle Casey; Claudie Gabillard-Lefort; Noel G McElvaney; Emer P Reeves
Journal:  Int J Mol Sci       Date:  2022-02-23       Impact factor: 5.923

3.  COVID-19 vaccination in patients with α1-antitrypsin deficiency.

Authors:  Chengliang Yang; Hedi Zhao
Journal:  Lancet Respir Med       Date:  2021-06-17       Impact factor: 30.700

4.  Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.

Authors:  Xiyuan Bai; Ashley M Buckle; Eszter K Vladar; Edward N Janoff; Reeti Khare; Diane Ordway; David Beckham; Lorelenn B Fornis; Abraham Majluf-Cruz; Randolph V Fugit; Brian M Freed; Soohyun Kim; Robert A Sandhaus; Edward D Chan
Journal:  Sci Rep       Date:  2022-03-25       Impact factor: 4.996
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.